International Space Station Astronauts at Work: Rocketing Biotechnology R&D to the Next Level

10:45 AM - 12:00 PM (PDT), Tuesday, June 14, 2022 ・ Ballroom

A new era in space-based scientific investigation started with the first all-private astronaut mission in April 2022 — a milestone in enabling the commercial potential of R&D in microgravity. An increasing number of companies are pursuing research in orbit with specific drug target identification or biomanufacturing benefits to accelerate product development pipelines back on Earth. Innovative public-private partnerships are growing the capacity, complexity, and availability of orbital R&D opportunities, making it easier than ever for biotechnology companies to participate.


See NASA astronaut Kjell Lindgren, MD, Crew-4 mission commander, explain from the International Space Station why microgravity experiments open new doors for biomedical research. Dr. Lindgren will answer the moderator’s questions live, and panelists from SpaceX, Axiom Space, Merck, and Redwirewill explore practical applications These experts will discuss the connection between the science conducted 250 miles above our heads with the practical steps to improve medicines, other products, and people’s lives at home here on Earth.

Moderator
photo
Editorial Director
MIT Technology Review
Speakers
photo
Vice President, Customer Operations and Integration
SpaceX
photo
Crew-4 Mission Commander, NASA Astronaut
National Aeronautics and Space Administration (NASA)
photo
Principal Investigator
Merck
photo
Chief Scientific Officer
Redwire